Filtrar resultados
Filtrar resultados
Integrated Biologics Advanced Synthesis Moléculas pequeñas Células y genes Specialized Modalities Cápsulas e ingredientes para la salud Corporativo Drug Product Services Tecnologías de expresión Licensing Mamíferos
Mammalian (97) Expression Technologies (62) Autologous (42) Parenteral Drug Product (42) Viral Vectors (42) Allogeneic (38) iPSCs (32) Microbial (21) Exosomes (18) Bioconjugates/ADC (17) mRNA (13)
Oral Drug Products (88) Bioavailability Enhancement (79) Monoclonal Antibody (73) Drug Substance (API/HPAPI) (63) Bispecific Antibody (57) Particle Engineering (46) Difficult to Express Proteins (40) Inhalation (32) Antibody Drug Conjugates (26) Fabs, Fusion, Scaffold and other Recombinant Proteins (21) Enhanced ADCC (12) Solid Form Services (11) Injectables (5) Lipid Nanoparticle Encapsulation (4) Drug device combinations (1)
Formulation Development and Optimization (81) Process Development and Optimization (72) Analytical Development (56) Cell Line Development (52) Clinical Supply Services (51) First-in-Human Services (51) Manufacturing: cGMP (51) Early De-risking & Optimization (38) API Services (36) Commercial Supply Services (35) Manufacturing: GMP Drug Substance (35) Regulatory Services (32) Manufacturing: GMP Drug Product (20) IND-to-BLA (18) Viral Vector Expression Technologies (15) Bispecific DNA-to-IND (12) Parenteral Drug Product Development (11) Immunogenicity Assessment (10) mAb DNA-to-IND: Ibex® Design (10) PBPK Modeling (9) Strain Development (6) Tissue Acquisition (6) Antibody Humanization & Deimmunization (5) Solid Form Services (5) Tech Transfer (5) Ibex® Dedicate (3) Manufacturing: Non-GMP Manufacture (3) Fabs and Fc-Fusion proteins DNA-to-IND (1) Scaffolds and Other Recombinant Proteins DNA-to-IND (1) Special Analytical Services (1)
Mammalian Expression Technologies (56) Spray Dried Dispersions (53) GS Xceed® Gene Expression System (41) GS Gene Expression System® (39) GS piggyBac® Transposon System (35) Hot Melt Extrusion (27) Particle Size Reduction (27) Cocoon® Platform (23) GSquad® Vectors (22) Microbial Expression Technologies (19) Technology Selection (19) Micronization (16) Viral Vector Expression Technologies (15) Micro-dosing/Powder-in-capsule (14) bYlok™ Bispecific Antibodies Technology (13) GS Effex® (12) Taste-masking and Multiparticulates (12) GS Discovery® (9) Modified and Delayed Release (9) XS Technologies® (7) 4D-Nucleofector LV (5) MODA® (5) LNP (4)
Webinar (on-demand) (127) White paper (95) Article (63) Peer-reviewed publication (44) Podcast (38) Technical/Service brief (37) Presentation (on-demand) (30) Poster (25) R&D Blog post (22) Video (17) e-book (15) Presentation (slides) (13) CDMO Notes Blog post (6) Interview (5) Report (1)
Reset Filters
   Cargando…
Showing 1‐28 of 500
Documento técnico
5 min read
Innovations in linking rational design and material-sparing strategies for enabled intermediates and their drug products
Did you catch our insightful webinar on Linking rational design and material-sparing strategies for enabled intermediates and their drug products? If not, or if you're looking for a concise recap of the key discussions, our new executive summary paper is ...
Seminario web (a pedido)
End-to-end regulatory CDMO solutions: development, manufacturing, and approval
Navigating the journey from drug development to market can feel like a maze, with each step presenting unique regulatory hurdles. That's why we hosted our insightful webinar, "End-to-end regulatory CDMO solutions: development, manufacturing, and approval,...
Documento técnico
4 min read
Seamless commercial tech transfers in OSD manufacturing
Remember our insightful webinar on Commercial tech transfers in OSD manufacturing? If you missed it, or want a short recap of the key takeaways, our comprehensive executive summary paper is now available. This paper distills the essential discussions and ...
Presentación (a pedido)
23 min read
Challenging your AAV productivity and packaging efficiencies through a validated platform
AAV transient and stable cell line platforms represent a leap into next-generation technologies that are set to drive gene therapy commercialization. Selecting the right manufacturing approach for AAV production is key to meeting productivity and scalabil...
CDMO Notes Blog post
8 min read
Using bespoke downstream processing strategies for the purification of complex novel protein-based therapeutics
Discover how Lonza's innovative downstream processing strategies can help you overcome the challenges of purifying complex novel therapeutics, ensuring optimal product quality and efficiency in bringing your molecules to the clinic.
Seminario web (a pedido)
Commercial Tech Transfers in OSD Manufacturing
This webinar explores the critical aspects of manufacturing commercial tech transfers for the manufacture of oral solid dosage (OSD) products. It provides insights into the progression of process validation for existing commercial products, ensuring consi...
Publicación del blog de I+D
4 min read
In-use stability and compatibility of Biologics – How to safely administer an effective medicinal product
Ensuring that patients receive the highest quality treatment under the best possible conditions is a fundamental priority in drug development.
Seminario web (a pedido)
50 min read
Rapid delivery of toxicological study material: The new critical path for accelerating biopharmaceutical drug development
With ever-increasing speed from DNA to IND, the window for toxicological data generation is becoming shorter and more critical. This necessitates innovative solutions to expedite the delivery of materials required for these vital studies, upon which an IN...
Documento técnico
5 min read
The Role of Excipients in Inhaled Biologics
The field of inhaled biologics is rapidly expanding, with both dry and liquid formulations of proteins, peptides, and nucleic acids gaining traction in clinical and commercial applications. Excipients are vital for ensuring the stability, safety, and eff...
CDMO Notes Blog post
6 min read
Accelerated Tox Offerings: A Recipe for Streamlining IND Applications
Accelerating the timeline to tox material can significantly enhance the drug development process, enabling faster IND submissions and providing crucial time savings for toxicology studies.
Seminario web (a pedido)
15 min read
Lonza Drug Product OPCU Capacity Update
Explore Lonza's end-to-end Drug Product capabilities along the full life cycle, seamlessly integrated with the drug substance network across biologic modalities. This presentation will highlight recent expansions at the Stein site in Switzerland, includin...
Seminario web (a pedido)
55 min read
De-Risking Early Phase Micronization with Integrated Solid Form Selection
Achieving the right particle size for respiratory drug delivery is crucial, and jet milling is a key technique. But how do you choose the right API solid form (salt, cocrystal, or solvate) for successful micronization and high yields? This webinar o...
Artículo
5 min read
Accelerating Drug Development with Precision Powder Micro-Dosing
Seminario web (a pedido)
30 min read
Producing Engineered Extracellular Vesicles with a Platform Approach
In this webinar, we'll discuss materials and methods to enable the expression of biomolecules on EVs. Data will be shared for using protein scaffolds, such as PTGFRN and BASP-1, that are clinically proven to effectively load therapeutic proteins on the su...
Publicación del blog de I+D
3 min read
Delivering a consistently excellent service with advanced process technologies
As a chemical engineer, it’s perhaps unsurprising that I find it immensely satisfying to use technology to solve problems. Over the past 20 years, I have built my career around finding better processes and techniques for pharmaceutical manufacturing by it...
CDMO Notes Blog post
6 min read
A Faster Path to the Clinic: Accelerating Biologics Development with Integrated Solutions
How Lonza’s team are helping to revolutionise the path to Biologics INDs, with an accelerated approach to drug development
Pódcast
2 min read
A View On mRNA Encapsulation (S04 E03)
In this episode, we are joined by three experts—Christoph Hein (Fraunhofer IPK), Bern-hard Bobusch (FDX Fluid Dynamix), and Sönke Stocker (Lonza)—to explore how ad-vanced fluidics, encapsulation techniques, and a truly collaborative approach are paving th...
Seminario web (a pedido)
60 min read
Accelerating Clinical Development: Modern Tools in Process Chemistry
This webinar explores how Lonza leverages High-Throughput Experimentation (HTE) and a model-based approach to enhance process development in early-phase projects. Designed to address the unique challenges faced by early-phase customers, the session will ...
Documento técnico
24 min read
From Discovery to Patients: an Integrated Service for ADC Development by Lonza and Synaffix
This white paper provides an in-depth look at the development and challenges of antibody-drug conjugates (ADCs) and how the Synaffix GlycoConnect™ platform, in collaboration with Lonza's Ibex® Design ADC program, addresses these challenges. ADCs are ther...
Peer-reviewed publication
Three-Dimensional Linkage Analysis With Digital PCR for Genome Integrity and Identity of Recombinant Adeno-Associated Virus
Abstract: Recombinant adeno-associated virus (rAAV) has emerged as the vector of choice for in vivo gene delivery, with numerous clinical trials underway for the treatment of various human diseases. Utilizing rAAV in gene therapy requires a highly precise...
Artículo
Women In Science Spotlight
Women In Science Spotlight featuring Inbar Friedrich Ben-Nun, Director of R&D, Lonza Cell & Gene Therapies
Documento técnico
15 min read
Exploring the Need for Dose-Flexible Manufacturing
Bringing a new drug to market is a complex journey, often involving various dosage forms throughout clinical development. From initial discovery to final product, the needs can shift dramatically. For example, pediatric and oncology medicines often requir...
Seminario web (a pedido)
Innovative AI-Driven Solutions to Address the Growing Complexity of APIs
Developing innovative medicines often involves intricate small-molecule APIs with lengthy synthetic routes. This complexity can significantly delay preclinical development and create challenges for supply chains. At Lonza Small Molecules, we've developed ...
Seminario web (a pedido)
57 min read
Charting a Successful CMC Journey for Your ADC Drug Product
Bioconjugates and Antibody drug conjugates (ADCs) are revolutionizing cancer therapy with their targeted mechanism of action, offering new hope to cancer patients worldwide. However, bioconjugates are highly complex molecules whose manufacturing presents ...
Entrevista
7 min read
Expert Q&A: Accelerate Your ADC Journey
Filling the Need for Integrated Bioconjugate Solutions Antibody drug conjugates (ADCs) are revolutionizing cancer therapy with their highly specific mechanism of action, offering new hope to cancer patients worldwide. To date, 14 ADCs have received mark...
Video
mRNA and LNP Encapsulation Capabilities at our Geleen/NL Center of Excellence
Discover how our team, with its impressive mRNA/LNP track record, can help you progress your project from research stages to pre-clinical development, clinical development, and finally commercialization. Key Characteristics: In-hous...
Artículo
6 min read
How Emerging Biotechs can Benefit by Partnering with a CDMO for Early Stage Development
The partnership between CDMOs and emerging biotech companies in early-stage development can be mutually beneficial. In this interview by PHARMAnetwork magazine, Dr. Raymond Donninger, Senior Director, Commercial Development, Early Development Services, an...
Pódcast
2 min read
A View On Antibody-Based Therapies (S04 E02)
In this episode, we are joined by Ronnie Wei, Head of Biologics Discovery and Devel-opment at ModeX Therapeutics, and Atul Mohindra, Head of R&D for Biologics at Lon-za, to explore the development and manufacturing of monoclonal, bi-, and multi-specific a...